Pre-clinical data demonstrated that anti-CD73 monoclonal antibodies (mAbs) significantly enhanced the activity of anti-CTLA-4 and anti-PD-1 mAbs in animal studies of colon, prostate, and breast cancer (118). Here, NT5E is linked to breast carcinoma.